Stille AB AI Stock Analysis
Want to see SE:STIL full AI Analyst Report?
Stille AB (STIL) AI Stock Analysis
Stille AB
(Nasdaq OMX AB:STIL)
Stille AB earns a strong overall score, primarily driven by its stellar financial execution, debt-free balance sheet, and record-breaking Q3 sales. Long-term technical trends remain firmly bullish, and its P/E ratio is well-justified by the impressive organic growth and continued margin expansion.
Stille AB (STIL) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 2.39B
- Dividend Yield
- ―
- Average Volume (3M)
- 9,556
- Price to Earnings (P/E)
- 24.8
- Beta (1Y)
- 0.28
- Revenue Growth
- 28.75%
- EPS Growth
- 138.25%
- Country
- Sweden
- Employees
- 239
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Stille AB Business Overview & Revenue Model
Company Description
Stille AB develops, manufactures, and distributes medtech products in Sweden and internationally. It operates through the Surgical Instruments and Surgical Tables segments. The Surgical Instruments segment offers surgical scissors, including SuperCut...
How the Company Makes Money
Stille makes money primarily by selling medical technology products to healthcare providers and related procurement channels. Key revenue streams include: (1) Sales of surgical instruments: revenue generated from manufacturing and supplying reusable...
Stille AB Earnings Call Summary
The call was strongly positive, with record rolling 12-month sales, robust organic growth, improved margins, sharply higher operating cash flow, stronger delivery performance, and a net cash position. The main challenges were elevated backorders, currency-related pressure on Surgical Instruments margins, partially outstanding tariff refunds, and management's caution that the exceptional 30% Surgical Tables growth rate is not expected to continue at the same level.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reiterated its long-term guidance to deliver +10% organic growth, an EBITDA margin of 25% and leverage of less than 3x net debt/EBITDA; it expects a gradual decrease in backorder level and a further reduction during Q4. Management said instrument-market growth is more a mid-single-digit growth and that +10% organic growth is a realistic target, while table sales growth of around 30% versus 2025 is clearly not a growth you should just extrapolate going into 2027 and 30% next year might be a stretch; no specific outlooks on individual segments, nor year by year outlook, were provided. Management’s target is to recover more tariff refunds, with the SEK 5.2 million received estimated at around 60% of what it would expect to see.
Stille AB Financial Statement Overview
Summary
Outstanding financial health characterized by a flawless 0.0 debt-to-equity ratio, expanding profit margins, and robust revenue and free cash flow generation.
Income Statement
88Very PositiveBalance Sheet
95Very PositiveCash Flow
84Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 711.42M | 567.63M | 569.95M | 294.89M | 246.35M | 187.09M |
| Gross Profit | 352.93M | 287.97M | 295.64M | 132.17M | 111.57M | 83.46M |
| EBITDA | 143.34M | 109.01M | 129.50M | 56.04M | 44.78M | 28.89M |
| Net Income | 96.27M | 55.70M | 58.21M | 26.65M | 27.32M | 16.10M |
Balance Sheet | ||||||
| Total Assets | 1.17B | 1.05B | 1.00B | 804.89M | 342.55M | 308.85M |
| Cash, Cash Equivalents and Short-Term Investments | 170.71M | 118.66M | 158.49M | 241.45M | 36.68M | 27.80M |
| Total Debt | 0 | 123.26M | 63.09M | 62.94M | 70.77M | 81.48M |
| Total Liabilities | 360.44M | 345.54M | 301.70M | 172.64M | 152.74M | 160.75M |
| Stockholders Equity | 809.76M | 708.71M | 699.40M | 632.25M | 189.81M | 148.10M |
Cash Flow | ||||||
| Free Cash Flow | 64.22M | 15.46M | 59.24M | 24.37M | 23.89M | -11.74M |
| Operating Cash Flow | 87.80M | 36.05M | 73.53M | 37.28M | 31.94M | 7.28M |
| Investing Cash Flow | -33.88M | -104.30M | -330.31M | -12.90M | -8.04M | -51.90M |
| Financing Cash Flow | -25.45M | 36.16M | 171.40M | 178.99M | -18.54M | 33.22M |
Stille AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STIL, the sentiment is Positive. The current price of 265.50 is above the 20-day moving average (MA) of 255.13, above the 50-day MA of 249.42, and above the 200-day MA of 232.07, indicating a bullish trend. The MACD of 2.43 indicates Negative momentum. The RSI at 62.44 is Neutral, neither overbought nor oversold. The STOCH value of 79.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:STIL.
Stille AB Peers Comparison
Overall Rating
SE:STIL83Outperform
SE:BONEX81Outperform
SE:ALIF.B74Outperform
SE:SUS73Outperform
SE:FLUO45Neutral
SE:OSSD45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | SEK 2.39B | 24.77 | ― | ― | 28.75% | 138.25% | |
| 81Outperform | SEK 21.15B | 77.77 | 29.00% | ― | 25.20% | 79.34% | |
| 74Outperform | SEK 22.21B | 34.62 | 11.32% | 0.82% | 1.62% | 63.45% | |
| 73Outperform | SEK 2.88B | 26.88 | ― | ― | 4.52% | 53.01% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 45Neutral | SEK 479.03M | -6.57 | ― | ― | ― | -23.57% | |
| 45Neutral | SEK 387.19M | -7.74 | ― | ― | -11.89% | -11.85% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:STIL | Stille AB | 265.50 | 95.00 | 55.72% | |
| SE:ALIF.B | AddLife AB Class B | 182.10 | 3.65 | 2.05% | |
| SE:BONEX | BONESUPPORT HOLDING AB | 321.20 | 119.20 | 59.01% | |
| SE:SUS | Surgical Science Sweden AB | 56.45 | -16.10 | -22.19% | |
| SE:OSSD | OssDsign AB | 3.50 | -7.48 | -68.12% | |
| SE:FLUO | FluoGuide A/S | 29.30 | -10.70 | -26.75% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026
